NASDAQ:ALBO Albireo Pharma (ALBO) News Today Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$43.99▼$44.9050-Day Range$43.50▼$44.9552-Week Range$16.02▼$45.23Volume1.24 million shsAverage Volume704,539 shsMarket Capitalization$913.91 millionP/E RatioN/ADividend YieldN/APrice Target$48.00 HeadlinesProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipOptions ChainSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineAlbireo Pharma (NASDAQ:ALBO) Coverage Initiated by Analysts at StockNews.commarketbeat.com - March 30 at 1:06 AMAlbireo Pharma, Inc. (NASDAQ:ALBO) Receives Consensus Rating of "Hold" from Analystsmarketbeat.com - March 27 at 6:16 AMStockNews.com Begins Coverage on Albireo Pharma (NASDAQ:ALBO)marketbeat.com - March 14 at 1:22 AMIpsen Pharma: Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfoliofinanznachrichten.de - March 4 at 6:49 PMFederated Hermes Inc. Has $43.72 Million Position in Albireo Pharma, Inc. (NASDAQ:ALBO)marketbeat.com - March 3 at 9:38 AMShort Interest in Albireo Pharma, Inc. (NASDAQ:ALBO) Declines By 19.8%marketbeat.com - March 3 at 7:58 AMTower Research Capital LLC TRC Boosts Stock Holdings in Albireo Pharma, Inc. (NASDAQ:ALBO)marketbeat.com - March 1 at 4:40 AMAlbireo Pharma, Inc. (NASDAQ:ALBO) Stock Position Trimmed by ExodusPoint Capital Management LPmarketbeat.com - February 27 at 4:38 AMALBO Albireo Pharma, Inc.seekingalpha.com - February 25 at 5:18 AMConnor Clark & Lunn Investment Management Ltd. Acquires New Shares in Albireo Pharma, Inc. (NASDAQ:ALBO)marketbeat.com - February 24 at 4:58 AMAlbireo Pharma, Inc. (ALBO)uk.finance.yahoo.com - February 18 at 11:00 PMPrudential Financial Inc. Sells 41,800 Shares of Albireo Pharma, Inc. (NASDAQ:ALBO)marketbeat.com - February 16 at 4:38 AMAlbireo Gets FDA Priority Review of Bylvay in Alagille Syndrome >ALBOmarketwatch.com - February 14 at 1:06 PMFDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndromefinance.yahoo.com - February 14 at 1:06 PMDekaBank Deutsche Girozentrale Grows Position in Albireo Pharma, Inc. (NASDAQ:ALBO)marketbeat.com - January 27 at 5:18 AMALBO.PH - | Stock Price & Latest News | Reutersreuters.com - January 24 at 10:55 AMWhy These Two Biotech Stocks Blasted Higher This Weekfinance.yahoo.com - January 21 at 9:04 AMHC Wainwright Weighs in on Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)marketbeat.com - January 13 at 7:43 AMCowen & Co. Downgrades Albireo Pharma: Here's What You Need To Knowmsn.com - January 11 at 3:22 PMAnalysts move to downgrade Albireo Pharma after Ipsen's proposed acquisitionmsn.com - January 11 at 3:22 PMAlbireo Pharma Spikes On Agreement To Be Acquired By Ipsennasdaq.com - January 11 at 10:21 AMExpert Ratings for Albireo Pharmamarkets.businessinsider.com - January 11 at 10:21 AMAlbireo Pharma (NASDAQ:ALBO) Rating Lowered to Neutral at Guggenheimmarketbeat.com - January 11 at 9:17 AMEquities Analysts Issue Forecasts for Albireo Pharma, Inc.'s FY2027 Earnings (NASDAQ:ALBO)marketbeat.com - January 10 at 7:59 AMShareholder Alert: Ademi LLP investigates whether Albireo Pharma, Inc. has obtained a Fair Price in its transaction with Ipsenbenzinga.com - January 9 at 2:48 PMALBO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Albireo Pharma, Inc. Is Fair to Shareholderstechnews.tmcnet.com - January 9 at 9:48 AMFrance-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipelinefinance.yahoo.com - January 9 at 9:48 AMAlbireo: Slowly Capturing Some Of The Liver Disease Marketseekingalpha.com - January 2 at 7:32 AMWe're Not Very Worried About Albireo Pharma's (NASDAQ:ALBO) Cash Burn Ratefinance.yahoo.com - December 21 at 3:29 PMAlbireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directorsfinance.yahoo.com - December 6 at 5:40 PMReimbursed Access to Bylvay® (odevixibat) Approved in France for Patients with PFIC 1 & 2finance.yahoo.com - November 30 at 12:30 PMFY2022 Earnings Estimate for Albireo Pharma, Inc. (NASDAQ:ALBO) Issued By William Blairmarketbeat.com - November 14 at 2:44 AMAlbireo Pharma (NASDAQ:ALBO) dips 16% this week as increasing losses might not be inspiring confidence among its investorsfinance.yahoo.com - November 10 at 8:47 AMAlbireo to Participate in Jefferies London Healthcare Conferencefinance.yahoo.com - November 9 at 10:19 AMAlbireo Pharma, Inc. (ALBO) Q3 2022 Earnings Call Transcriptseekingalpha.com - November 9 at 1:50 AMAlbireo Reports Q3 2022 Financial Results and Business Updatefinance.yahoo.com - November 8 at 8:48 PMAlbireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimatesfinance.yahoo.com - November 8 at 8:48 PMBylvay® (odevixibat) Data Presented at AASLD The Liver Meeting® 2022, Demonstrating Native Liver Survival in Children Across PFIC Typesfinance.yahoo.com - November 7 at 9:07 AMAlbireo Announces 2022 SPARK Grant Winnersfinance.yahoo.com - November 3 at 9:48 AMAlbireo Completes Phase 3 BOLD Study Enrollment of Bylvay(R) in Biliary Atresiafinance.yahoo.com - November 2 at 11:47 AMAlbireo to Present Late Breaking Bylvay® (odevixibat) Data at AASLD 2022finance.yahoo.com - November 1 at 11:37 AMAlbireo to Report Q3 2022 Financial Results on November 8, 2022finance.yahoo.com - October 31 at 8:55 AMAnalysts Expect Mirum Pharma's Liver Disease Candidate Might Exceed Rival Product's Penetrationfinance.yahoo.com - October 25 at 10:25 PMInsider Selling: Albireo Pharma, Inc. (NASDAQ:ALBO) CEO Sells 919 Shares of Stockmarketbeat.com - October 25 at 5:58 PMAlbireo Pharma (NASDAQ:ALBO) Price Target Raised to $59.00 at Guggenheimmarketbeat.com - October 17 at 3:08 AMAlbireo Pharma, Inc. (NASDAQ:ALBO) Short Interest Down 13.3% in Septembermarketbeat.com - October 15 at 5:26 AMQ3 2022 EPS Estimates for Albireo Pharma, Inc. (NASDAQ:ALBO) Increased by Analystmarketbeat.com - October 14 at 7:13 AMAlbireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHANfinance.yahoo.com - October 13 at 11:38 AMAlbireo Presents Data on Greater Efficacy in PFIC with Earlier Bylvay® Treatment at NASPGHANfinance.yahoo.com - October 13 at 11:38 AMAlbireo: Strong Phase 3 Data Foretells More Upsideseekingalpha.com - October 12 at 8:23 PM Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address ALBO Media Mentions By Week ALBO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALBO News Sentiment▼0.200.68▲Average Medical News Sentiment ALBO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALBO Articles This Week▼02▲ALBO Articles Average Week Get Albireo Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SLRN News ARDX News KROS News INVA News BLTE News DCPH News PHAR News PLRX News AVDL News COGT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:ALBO) was last updated on 9/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Albireo Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.